Matthew Norkunas
Direttore Finanziario/CFO presso GENERATION BIO CO.
Patrimonio netto: 158 392 $ in data 30/04/2024
Posizioni attive di Matthew Norkunas
Società | Posizione | Inizio | Fine |
---|---|---|---|
GENERATION BIO CO. | Comptroller/Controller/Auditor | 22/07/2020 | - |
Direttore Finanziario/CFO | 22/07/2020 | - | |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 23/05/2023 | - |
Storia della carriera di Matthew Norkunas
Precedenti posizioni note di Matthew Norkunas
Società | Posizione | Inizio | Fine |
---|---|---|---|
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Direttore Finanziario/CFO | 01/01/2016 | 01/06/2020 |
Marsico Capital Management LLC
Marsico Capital Management LLC Investment ManagersFinance Marsico Capital Management LLC (MCM) is a SEC-registered investment advisor and mutual fund manager headquartered in Denver, Colorado. The firm was founded by Thomas “Tom” Marsico in 1997. MCM manages assets for mutual funds, corporate retirement plans, endowments, foundations, family offices, separately managed wrap programs, and other clients. The firm also serves as the investment adviser to the Marsico Funds. | Analyst-Equity | 01/07/2012 | - |
Formazione di Matthew Norkunas
St. Mary's College (Maryland) | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
University of Maryland School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Director of Finance/CFO | 2 |
Analyst-Equity | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 4 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
GENERATION BIO CO. | Health Technology |
Aziende private | 3 |
---|---|
Marsico Capital Management LLC
Marsico Capital Management LLC Investment ManagersFinance Marsico Capital Management LLC (MCM) is a SEC-registered investment advisor and mutual fund manager headquartered in Denver, Colorado. The firm was founded by Thomas “Tom” Marsico in 1997. MCM manages assets for mutual funds, corporate retirement plans, endowments, foundations, family offices, separately managed wrap programs, and other clients. The firm also serves as the investment adviser to the Marsico Funds. | Finance |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Matthew Norkunas
- Esperienza